Why Immunome Stock Surged Today
The oncology specialist's targeted therapies could improve thousands of lives.Shares of Immunome (IMNM +15.51%) jumped over 15% on Monday after the biotech company announced positive clinical results for varegacestat, an investigational treatment for patients with progressing desmoid tumors. A destructive diseaseDesmoid tumors can be debilitating and lead to life-threatening organ damage. Each year, 1,000 to 1,650 people are diagnosed with the health condition in the U.S. alone."Desmoid tumors can have a d ...